Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Exp Ther Med. 2013 Dec;6(6):1499-1503. Epub 2013 Oct 14.

Role of S100A3 in human colorectal cancer and the anticancer effect of cantharidinate.

Author information

  • 1Department of General Surgery, Jilin University Second Hospital, Changchun, Jilin 130041, P.R. China.

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related mortality. The early diagnosis and treatment of CRC is the key to improving the survival of patients who may benefit from adjuvant chemotherapy. In the present study, the protein expression of S100A3 was observed in a cohort of 20 patients with cancer, which indicated that S100A3 activation was involved in tumorigenesis. In addition, the anticancer activity of cantharidinate was investigated using immunohistochemistry and quantitative polymerase chain reaction (qPCR) analysis. The protein expression of S100A3 was observed to increase by 2.4-fold in human CRC cells compared with the expression level in normal control cells (P<0.01). Cantharidinate inhibited the protein and gene expression of S100A3 in UCT-116 human CRC cells in vitro. These results suggested that S100A3 is important in human CRC. Cantharidinate has the potential to be considered as a novel adjuvant drug for controlling the expression of S100A3 in human CRC as it exhibits preventive effects.

KEYWORDS:

S100A3; cantharidinate; colorectal cancer

PMID:
24255681
[PubMed]
PMCID:
PMC3829748
Free PMC Article

Images from this publication.See all images (5)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk